Predict your next investment

Corporation
CONSUMER PRODUCTS & SERVICES | Health & Wellness (non-internet/mobile)

See what CB Insights has to offer

Founded Year

2000

Stage

IPO | IPO

About Agtech Global International

Agtech Global International (OTCMKTS: AGGL) operates in the premium CBD consumer products sector.

Agtech Global International Headquarter Location

Newport Beach, California,

United States

Latest Agtech Global International News

Agtech Appoints Leading Harvard Trained Medical Expert as Chief Science Officer

Dec 9, 2021

Galexxy Holdings Inc. CALIFORNIA, Newport Beach, Dec. 09, 2021 (GLOBE NEWSWIRE) -- Agtech Global International, Inc. (Agtech) (name change to Galexxy Holdings Inc. in process) (OTC Pink: AGGL) is pleased to announce the appointment of Dr. Malcolm A. Leissring as its Chief Science Officer (CSO) effective January 1, 2022. This appointment follows Agtech’s recent agreement to acquire NooMeds, LLC., a company formed by Dr. Leissring to market A.L.Z. Defense™, a scientifically tested dietary supplement shown to prevent memory problems in laboratory models of Alzheimer’s disease. Dr. Leissring is an award-winning neuroscientist who is internationally recognized for his work on the molecular pathogenesis of Alzheimer’s disease and diabetes, with an emphasis on drug discovery and development. He conducted his postdoctoral training at Harvard Medical School in the laboratory of Dennis J. Selkoe, M.D., one of the world’s leading researchers in Alzheimer’s disease. His research has been funded by grants from the National Institutes of Health (NIH) and numerous private foundations. For his pioneering work on Alzheimer’s disease and diabetes, Dr. Leissring has received awards from many prestigious organizations, such as the Alzheimer’s Association, the Ellison Medical Foundation, the American Federation for Aging Research and the American Diabetes Association. Dr. Leissring was recently awarded a $3 million grant from the NIH’s National Institute on Aging to continue his research on Alzheimer’s disease at the University of California, Irvine. In his role as CSO of Agtech/Galexxy, Dr. Leissring will help direct the research and drug development program for the novel compounding of psilocybin and cannabidiol (CBD) into proprietary formulations. This program is being conducted by KRTL Biotech, Inc. in South Korea. Dr. Leissring added, “I’m excited by this KRTL drug development opportunity to help formally evaluate the therapeutic potential of highly promising compounds that have been in use for millennia, but have been off limits to investigators until only recently.”  Agtech is publicly traded on the OTC Markets (OTC Pink: AGGL). Headquartered in Newport Beach, California, Agtech is entering the rapidly developing markets for premium CBD consumer products through its recent acquisition of Galexxy Corporation and its joint venture with City Farm Industries. Agtech’s “soil-to-sale” business strategy is keenly focused on controlling the supply chain and maximizing profits. Agtech Global International, Inc.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.